6 melanoma helper peptide vaccine
Term · Oncology and biomedicine · MLC-T-ONC-009554
A multi-epitope vaccine containing the following six class II MHC-restricted peptides: gp100, MelanA/MART-1, two tyrosinase peptides, and the cancer/testis antigens MAGE-A3 and MAGE-A1,2,3,6, with potential antineoplastic activity. Upon administration, melanoma helper peptides induce an antigen-specific, Th1-dominant, CD4+ T-cell response, potentially augmenting cytotoxic T-cell (CTL) responses and maintaining immunologic memory against tumor cells expressing melanoma-specific antigens. The 6MHP vaccine may also induce a CD8+ T-cell response through epitope spreading, potentially priming subsequent immune responses against tumor cells.
| Identifier | MLC-T-ONC-009554 |
|---|---|
| Field | Oncology and biomedicine |
| Abbreviation | 6MHP |
| Synonyms | 6MHP vaccine |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-009554",
"term": "6 melanoma helper peptide vaccine",
"field": "Oncology and biomedicine",
"definition": "A multi-epitope vaccine containing the following six class II MHC-restricted peptides: gp100, MelanA/MART-1, two tyrosinase peptides, and the cancer/testis antigens MAGE-A3 and MAGE-A1,2,3,6, with potential antineoplastic activity. Upon administration, melanoma helper peptides induce an antigen-specific, Th1-dominant, CD4+ T-cell response, potentially augmenting cytotoxic T-cell (CTL) responses and maintaining immunologic memory against tumor cells expressing melanoma-specific antigens. The 6MHP vaccine may also induce a CD8+ T-cell response through epitope spreading, potentially priming subsequent immune responses against tumor cells.",
"abbreviation": "6MHP",
"synonyms": [
"6MHP vaccine"
],
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/6-melanoma-helper-peptide-vaccine/"
}
Record 120 of 17,717 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.